Updated:
Predictive Oncology Inc.
Welcome to Predictive Oncology The leading edge of a new frontier in drug discovery Integrating scientific rigor with machine learning • Overcoming challenges...
Predictive Oncology Inc.
Welcome to Predictive Oncology The leading edge of a new frontier in drug discovery Integrating scientific rigor with machine learning • Overcoming challenges of clinical trials • Improving the probability of success • Collaborating with partners in biopharma • Advancing molecules to medicine with confidence and accuracy Connect with us Changing the game in drug […]
General information
Firm type
Asset Manager
Location
Region
North America
Country
United States
City
Pittsburgh
Corporate office
91 43rd Street Suite 110, Pittsburgh, PA 15201, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Predictive Oncology?
Predictive Oncology Inc. is a publicly traded company (NASDAQ: POAI) with a board of directors and executive management team. The firm does not disclose individual investment decision-makers publicly, and no named principals were found in available sources.
How does Predictive Oncology source proprietary deal flow?
Predictive Oncology sources proprietary deal flow through its offerings in drug discovery and clinical testing services. The company's biobank of over 150,000 tumor samples and its AI platform attract biopharma partners seeking drug-response testing and prediction, generating revenue from service contracts rather than venture-style investments.
Is Predictive Oncology structured as a family office or does it operate more like a venture firm?
Predictive Oncology Inc. is a publicly traded corporation (NASDAQ: POAI) that operates as a drug discovery and testing services firm. It is not structured as a family office or venture firm; it generates revenue by providing predictive modeling and laboratory services to biopharmaceutical partners.
Does Predictive Oncology participate in fund commitments or only direct deals?
Predictive Oncology does not participate in fund commitments. It is a service provider that uses its AI platform and tumor biobank to assist biopharma partners in drug development. The firm's revenue comes from service contracts, not from investing in external funds or making direct investments.
What investment stages does Predictive Oncology typically target?
Predictive Oncology is not an investment firm; it is a drug discovery and testing company. It targets the pre-clinical and early clinical development stages of the pharmaceutical pipeline, helping partners select drug candidates and predict efficacy before expensive clinical trials.
Which sectors does Predictive Oncology explicitly avoid?
Predictive Oncology explicitly focuses on oncology and drug discovery. The firm does not target sectors outside of cancer therapeutics and drug development, including no exposure to finance, real estate, or technology unrelated to healthcare.
Does Predictive Oncology maintain philanthropic structures?
There is no public information indicating that Predictive Oncology Inc. maintains philanthropic foundations or charitable arms. The firm appears to operate as a for-profit, publicly traded entity solely focused on its drug discovery and testing business.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: